The goal of cardiovascular research is to understand the molecular mechanisms of cardiovascular disease (CVD) and to develop new strategies for its treatment and prevention. Atherosclerosis is a major component of CVD. In atherosclerosis, the development of plaques in arterial walls involves abnormal lipid metabolism and chronic inflammation. It is clear that the immune system plays a key role in this process. Related areas of research include identifying the genes that predict risk for atherosclerosis, and to understand the molecular basis of blood clot formation. Cardiovascular research also includes the study of the genetic abnormalities that cause inappropriate signaling within the damaged heart resulting from congestive heart failure, and the genes and molecular mechanisms that lead to the formation of the heart and blood vessels.
Bethyl’s cardiovascular portfolio consists of more than 4,700 antibodies. Our antibodies have been manufactured on-site by Bethyl scientists. Our rigorous validation process ensures that the antibody will work in the applications outlined on the datasheet. These applications include: Western blot, immunohistochemistry, immunoprecipitation, immunocytochemistry, flow cytometry, proximity ligation assay, and ChIP. A Bethyl antibody is first validated for specificity in immunoprecipitation and/or western blot and if it passes our team will validate the antibody for additional applications. Our products are backed with a 100% guarantee to work in your assay, when used in under the same conditions outlined on the product datasheet, which provides confident, reliable results.
Bethyl sells a wide variety of antibodies for the study of cardiovascular. Recent publications using our antibodies for studying cardiovascular include:
Below is the entire list of targets involved in cardiovascular research. Can’t find what you are looking for? Bethyl offers a custom antibody service.